These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 11335698

  • 1. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A.
    Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).
    Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.
    Neurology; 2003 Jan 14; 60(1):31-6. PubMed ID: 12525714
    [Abstract] [Full Text] [Related]

  • 4. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.
    Ramp M, Khan F, Misajon RA, Pallant JF.
    Health Qual Life Outcomes; 2009 Jun 22; 7():58. PubMed ID: 19545445
    [Abstract] [Full Text] [Related]

  • 5. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.
    Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ.
    Mult Scler; 2003 Aug 22; 9(4):411-9. PubMed ID: 12926848
    [Abstract] [Full Text] [Related]

  • 6. Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients.
    Rogić Vidaković M, Šimić N, Poljičanin A, Nikolić Ivanišević M, Ana J, Đogaš Z.
    Mult Scler Relat Disord; 2021 May 22; 50():102850. PubMed ID: 33636617
    [Abstract] [Full Text] [Related]

  • 7. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
    Rosti-Otajärvi E, Hämäläinen P, Wiksten A, Hakkarainen T, Ruutiainen J.
    Brain Behav; 2017 Jul 22; 7(7):e00725. PubMed ID: 28729932
    [Abstract] [Full Text] [Related]

  • 8. Comparison of patient-reported outcome measures in multiple sclerosis.
    Schäffler N, Schönberg P, Stephan J, Stellmann JP, Gold SM, Heesen C.
    Acta Neurol Scand; 2013 Aug 22; 128(2):114-21. PubMed ID: 23398571
    [Abstract] [Full Text] [Related]

  • 9. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).
    Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ, Zajicek JP.
    Brain; 2006 Jan 22; 129(Pt 1):224-34. PubMed ID: 16280352
    [Abstract] [Full Text] [Related]

  • 10. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
    Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ.
    J Neurol Neurosurg Psychiatry; 2002 Dec 22; 73(6):701-4. PubMed ID: 12438473
    [Abstract] [Full Text] [Related]

  • 11. Cross-cultural adaptation and validation of the Arabic version of the Multiple Sclerosis Impact Scale-29.
    Albishi AM, Alruwaili MB, Alsubiheen AM, Alnahdi AH, Alokaily AO, Algabbani MF, Alrahed Alhumaid LA, Alderaa AA, Aljarallah S.
    Disabil Rehabil; 2024 May 13; ():1-8. PubMed ID: 38738778
    [Abstract] [Full Text] [Related]

  • 12. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL, Zwemmer JN, Jelles B, Polman CH, Uitdehaag BM.
    Mult Scler; 2004 Oct 13; 10(5):569-74. PubMed ID: 15471375
    [Abstract] [Full Text] [Related]

  • 13. Development and validation of an audit instrument: the Prostate Outcomes Questionnaire.
    Lamping DL, Rowe P, Black N, Lessof L.
    Br J Urol; 1998 Jul 13; 82(1):49-62. PubMed ID: 9698662
    [Abstract] [Full Text] [Related]

  • 14. Validation of the fatigue severity scale in Croatian population of patients with multiple sclerosis disease: Factor structure, internal consistency, and correlates.
    Jerković A, Proroković A, Matijaca M, Katić AĆ, Košta V, Mihalj M, Dolić K, Đogaš Z, Vidaković MR.
    Mult Scler Relat Disord; 2022 Feb 13; 58():103397. PubMed ID: 35216780
    [Abstract] [Full Text] [Related]

  • 15. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
    Gray O, McDonnell G, Hawkins S.
    Mult Scler; 2009 Jan 13; 15(1):75-80. PubMed ID: 18829636
    [Abstract] [Full Text] [Related]

  • 16. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.
    Hobart J, Cano S.
    Health Technol Assess; 2009 Feb 13; 13(12):iii, ix-x, 1-177. PubMed ID: 19216837
    [Abstract] [Full Text] [Related]

  • 17. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis.
    Freeman JA, Hobart JC, Langdon DW, Thompson AJ.
    J Neurol Neurosurg Psychiatry; 2000 Feb 13; 68(2):150-6. PubMed ID: 10644779
    [Abstract] [Full Text] [Related]

  • 18. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C, Hutchinson M.
    J Neurol Neurosurg Psychiatry; 2004 Feb 13; 75(2):266-9. PubMed ID: 14742602
    [Abstract] [Full Text] [Related]

  • 19. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales.
    Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.
    J Neurol Neurosurg Psychiatry; 2005 Nov 13; 76(11):1539-43. PubMed ID: 16227547
    [Abstract] [Full Text] [Related]

  • 20. Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
    Hobart J, Freeman J, Thompson A.
    Brain; 2000 May 13; 123 ( Pt 5)():1027-40. PubMed ID: 10775547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.